InvestorsHub Logo

LilyGDog

01/26/21 8:17 AM

#341561 RE: BonelessCat #341535

Great post LilKahuna. And, there is not as much money in curing people with a therapeutic vs. inoculating billions with a vaccine each year.

Go Leo & IPIX!

Quote:
15yrs and nothing seen-through to approval. Nothing seen through a P3 even.

Not unusual. Yes, including the time for Polymedix prior to IPIX, B has been in development for 15 years. When there is no urgent need, or there’s been no government focus, vaccines and therapeutics can take decades.

The current spate of mRNA vaccines have been in development for more than 30 years. If it weren’t for a pandemic Big Pharma was probably at least 5 years or more away from consideration of approval. More importantly, last March the Covid task force prioritized vaccines over therapeutics. Lots of money for vaccines, almost none for therapeutics.

Now that there are vaccines, the focus will turn to therapies for those the vaccines have yet to reach. At 1.5 million doses a day, the US is still at least 6 months from herd immunity. Moreover, there is still a month or two lag period to get the next 100 million doses manufactured and distributed.

Therapeutic use for Brilacidin is now becoming urgent as deaths are 4 to 8 weeks behind infections. If B works, it will likely reduce time of infection, tissue damage and recovery time. We should all pray that Covid victims see immediate relief beginning with patient 1. Patient 1 is anticipated by end of next week if the trial begins this week as PRed.

wsbc

01/26/21 12:00 PM

#341600 RE: BonelessCat #341535

Drugs in development cost money until they make money. Leo's paying on the patent, and the patent has a finite lifespan. Between paying on the patent and paying himself and his several employees, he's eaten almost his entire budget for years, with almost nothing left over for trials (you can read the Q's for yourself and look at the balance sheets). Time is money. Leo has no money. This is a colossal part of our issue.

I feel like a broken record every time I say this.

I'm speaking generally too, not just about Brilacidin.

15yrs is on the far-end of the timeline, which is why I made the point.
Total time of development on average for drugs including P3 and final approval if funded properly is closer to 10yrs.
http://phrma-docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf
Sort of highlights the need for a partner, and it's worth a read if you haven't already. It's general.

B-Covid should be progressing SIGNIFICANTLY more rapidly than it is, given the government support programmes in place and the fact that this is during a Pandemic with a global immediate need. EVERYthing is fast-tracked. Except for Brilacidin apparently.

Where the hell is the trial?
Since July 2020 it's been '4Q 2020'... now '...in Jan '21'
... and now we have radio silence.

Where is Leo?

Not unusual. Yes, including the time for Polymedix prior to IPIX, B has been in development for 15 years. When there is no urgent need, or there’s been no government focus, vaccines and therapeutics can take decades.

The current spate of mRNA vaccines have been in development for more than 30 years. If it weren’t for a pandemic Big Pharma was probably at least 5 years or more away from consideration of approval. More importantly, last March the Covid task force prioritized vaccines over therapeutics. Lots of money for vaccines, almost none for therapeutics.

Now that there are vaccines, the focus will turn to therapies for those the vaccines have yet to reach. At 1.5 million doses a day, the US is still at least 6 months from herd immunity. Moreover, there is still a month or two lag period to get the next 100 million doses manufactured and distributed.

Therapeutic use for Brilacidin is now becoming urgent as deaths are 4 to 8 weeks behind infections. If B works, it will likely reduce time of infection, tissue damage and recovery time. We should all pray that Covid victims see immediate relief beginning with patient 1. Patient 1 is anticipated by end of next week if the trial begins this week as PRed.